País: Estats Units
Idioma: anglès
Font: NLM (National Library of Medicine)
BUSPIRONE HYDROCHLORIDE (UNII: 207LT9J9OC) (BUSPIRONE - UNII:TK65WKS8HL)
NCS HealthCare of KY, Inc dba Vangard Labs
BUSPIRONE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE 5 mg
ORAL
PRESCRIPTION DRUG
Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three o
Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “5” on one side, “5663” on the reverse side containing 5 mg buspirone hydrochloride, packaged in blisterpacks of 30 tablets . Buspirone Hydrochloride Tablets USP are available as white, oval tablets debossed with an hourglass logo, breakline and “10” on one side, “5664” on the reverse side containing 10 mg buspirone hydrochloride, packaged in blisterpacks of 30 and 31 tablets. Buspirone Hydrochloride Tablets USP are available as white, capsule-shaped tablets debossed with “5”, breakline, “5”, breakline, “5” on one side, an hourglass logo, breakline, “56”, breakline, “65” on the reverse side containing 15 mg buspirone hydrochloride, packaged in blisterpacks of 30 and 31 tablets. PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required). Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Protect from temperatures greater than 86°F (30°C).
Abbreviated New Drug Application
BUSPIRONE HYDROCHLORIDE- BUSPIRONE HYDROCHLORIDE TABLET NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- BUSPIRONE HYDROCHLORIDE TABLETS USP DESCRIPTION Buspirone hydrochloride is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Buspirone hydrochloride is a white crystalline, water soluble compound and is chemically designated as _N_-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-1,1-cyclopentanedi-acetamide monohydrochloride. It has the following structural formula: C H N O •HCl M.W. 422.0 Buspirone hydrochloride is supplied as tablets for oral administration containing 5 mg, 10 mg, or 15 mg of buspirone hydrochloride (equivalent to 4.6 mg, 9.1 mg, or 13.7 mg of buspirone free base respectively). The 5-mg and 10-mg tablets are scored so they can be bisected. Thus, the 5-mg tablet can also provide a 2.5-mg dose, and the 10-mg tablet can provide a 5-mg dose. The 15 mg tablet is scored so it can be either bisected or trisected. Thus, a single 15-mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). Buspirone tablets contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. CLINICAL PHARMACOLOGY The mechanism of action of buspirone is unknown. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. _In vitro_ preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT ) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding _in vitro_ or _in vivo_ when tested in preclinical models. Buspirone has moderate affinity for brain D -dopamine receptors. Some studies d Llegiu el document complet